StockNote
DTH
Thanh Hoa Pharmaceutical and Medical Supplies Joint Stock Company (DTH), formerly known as the State Enterprise, was established in 1961, operating in the field of medicine and pharmaceuticals. The main business of the company is the production and trading of oriental medicines, neo-medicine, functional foods. Some of the company's main products today are: Hyaluronic acid, BIOFIL supplements, minerals and vitamins of all kinds. The company has 02 factories meeting who – GMP standards, namely Dong Duoc Drug Factory (Northwest Ga Industrial Park – Thanh Hoa City) and Tan Duoc Drug Factory. DTH's products are present in the general hospital system in 64 provinces and medical centers such as Central Eye Institute, Central Children's Hospital, Bach Mai Hospital... DTH is officially traded in UPCoM Market from April 18, 2022.
DTH currently has a market capitalization of roughly VND 118 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 33x is 5% below its own 3-year average (34,6x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 0,8x, 1% below its multi-year average of 0,9x. Return on equity (ROE) is at 2,6%. Its debt-to-equity ratio of 0,8x is moderate, reflecting a balanced capital structure. In 2025, revenue fell 9% year-on-year while after-tax profit grew 1%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Not enough data for this period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.